Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

News   Nov 18, 2017

 
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
 
 
 

RELATED ARTICLES

Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug Development

News

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

READ MORE

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

News

New programs added in respiratory and cardio-metabolic diseases.

READ MORE

Protein Acts as Brake on Learning and Memory

News

Researchers have discovered a new way that the protein RGS14 functions as a molecular brake on learning and memory

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE